• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

作者信息

Miyazaki Isao, Odintsov Igor, Ishida Keiji, Lui Allan J W, Kato Masanori, Suzuki Tatsuya, Zhang Tom, Wakayama Kentaro, Kurth Renate I, Cheng Ryan, Fujita Hidenori, Delasos Lukas, Vojnic Morana, Khodos Inna, Yamada Yukari, Ishizawa Kota, Mattar Marissa S, Funabashi Kaoru, Chang Qing, Ohkubo Shuichi, Yano Wakako, Terada Ryuichiro, Giuliano Claudio, Lu Yue Christine, Bonifacio Annalisa, Kunte Siddharth, Davare Monika A, Cheng Emily H, de Stanchina Elisa, Lovati Emanuela, Iwasawa Yoshikazu, Ladanyi Marc, Somwar Romel

机构信息

Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3.

DOI:10.1038/s43018-023-00663-3
PMID:37814012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10597837/
Abstract
摘要

相似文献

1
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.作者更正：维帕替尼是一种药理学上先进的RET选择性抑制剂，具有高中枢神经系统渗透性和对RET溶剂前沿突变的抑制活性。
Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3.
2
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.威帕他尼是一种药理先进的 RET 选择性抑制剂，具有较高的中枢神经系统穿透性和对 RET 溶剂前沿突变的抑制活性。
Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21.
3
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants.维帕替尼：一种具有增强中枢神经系统渗透性的RET选择性抑制剂，可靶向治疗耐药突变体。
Nat Cancer. 2023 Sep;4(9):1220-1221. doi: 10.1038/s43018-023-00631-x.
4
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.RET 融合阳性非小细胞肺癌中对选择性 RET 酪氨酸激酶抑制剂耐药的机制。
Ann Oncol. 2020 Dec;31(12):1725-1733. doi: 10.1016/j.annonc.2020.09.015. Epub 2020 Sep 29.
5
1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.1-甲基-3-((4-(喹啉-4-基氧基)苯基)氨基)-1H-吡唑-4-甲酰胺衍生物作为新型转染期间重排（RET）激酶抑制剂，能够抑制溶剂前沿区域的耐药突变体。
Eur J Med Chem. 2022 Dec 15;244:114862. doi: 10.1016/j.ejmech.2022.114862. Epub 2022 Oct 21.
6
RET kinase inhibitors for -altered thyroid cancers.用于RET基因改变的甲状腺癌的RET激酶抑制剂。
Ther Adv Med Oncol. 2022 Jun 21;14:17588359221101691. doi: 10.1177/17588359221101691. eCollection 2022.
7
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.追逐靶点：肺癌中对新型选择性RET抑制剂耐药的新现象。最新证据与未来展望。
Cancers (Basel). 2021 Mar 4;13(5):1091. doi: 10.3390/cancers13051091.
8
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.RET抑制剂凡德他尼与mTOR抑制剂依维莫司联合用于伴有脑转移的KIF5B-RET重排非小细胞肺癌的全身及中枢神经系统活性
Lung Cancer. 2015 Jul;89(1):76-9. doi: 10.1016/j.lungcan.2015.04.004. Epub 2015 Apr 22.
9
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.L730V/I RET 屋顶突变对普拉替尼和塞尔帕替尼表现出不同的活性。
NPJ Precis Oncol. 2021 Jun 7;5(1):48. doi: 10.1038/s41698-021-00188-x.
10
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.RET 驱动的肺和甲状腺癌中 RET 抑制剂耐药的演变。
Nat Commun. 2022 Mar 18;13(1):1450. doi: 10.1038/s41467-022-28848-x.